- Home
- FSP vs KYTX Comparison
FSP vs KYTX Comparison
Compare FSP & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSP
- KYTX
- Stock Information
- Founded
- FSP 1981
- KYTX 2018
- Country
- FSP United States
- KYTX United States
- Employees
- FSP N/A
- KYTX N/A
- Industry
- FSP Real Estate Investment Trusts
- KYTX
- Sector
- FSP Real Estate
- KYTX
- Exchange
- FSP Nasdaq
- KYTX NYSE
- Market Cap
- FSP 199.9M
- KYTX 196.4M
- IPO Year
- FSP N/A
- KYTX 2024
- Fundamental
- Price
- FSP $1.91
- KYTX $3.98
- Analyst Decision
- FSP
- KYTX Buy
- Analyst Count
- FSP 0
- KYTX 5
- Target Price
- FSP N/A
- KYTX $23.20
- AVG Volume (30 Days)
- FSP 510.9K
- KYTX 453.0K
- Earning Date
- FSP 10-29-2024
- KYTX 02-12-2025
- Dividend Yield
- FSP 2.09%
- KYTX N/A
- EPS Growth
- FSP N/A
- KYTX N/A
- EPS
- FSP N/A
- KYTX N/A
- Revenue
- FSP $126,508,000.00
- KYTX N/A
- Revenue This Year
- FSP N/A
- KYTX N/A
- Revenue Next Year
- FSP $0.02
- KYTX N/A
- P/E Ratio
- FSP N/A
- KYTX N/A
- Revenue Growth
- FSP N/A
- KYTX N/A
- 52 Week Low
- FSP $1.47
- KYTX $3.63
- 52 Week High
- FSP $2.72
- KYTX $30.60
- Technical
- Relative Strength Index (RSI)
- FSP 50.83
- KYTX 38.40
- Support Level
- FSP $1.83
- KYTX $3.63
- Resistance Level
- FSP $2.21
- KYTX $4.60
- Average True Range (ATR)
- FSP 0.13
- KYTX 0.45
- MACD
- FSP -0.00
- KYTX -0.10
- Stochastic Oscillator
- FSP 33.33
- KYTX 8.58
About FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.